Neuro said: < I have in the past argued for negotiating from strength, and I do know that licensees look for companies who are fiscally weak, and build that into their strategies >
This I am sure is correct. Keep in mind also that if two or more BPs are competing for CX717, it will be the science and the product potential that will drive the deal, not the current COR cash balance.